INCYTE Executive and Leadership Team

William Meury, the President & Chief Executive Officer at INCYTE, directs the company's overarching strategy and operational execution. Overseeing all facets of the biopharmaceutical enterprise, Meury ensures the effective discovery, development, and commercialization of novel therapeutics. This leadership role involves guiding the organization's mission to address critical unmet medical needs, particularly in oncology. By fostering a culture of scientific rigor and patient-centricity, William Meury drives the company's pursuit of groundbreaking treatments. The President & Chief Executive Officer's responsibilities extend to managing key stakeholder relationships and ensuring alignment with corporate objectives, thereby solidifying INCYTE's market position and advancing its pipeline.

Suky Upadhyay, the Executive Vice President & Chief Financial Officer at INCYTE, directs the company's financial strategy and fiscal operations. Overseeing all financial planning, reporting, and capital allocation, Upadhyay ensures the robust financial health necessary for INCYTE's biopharmaceutical endeavors. This pivotal role supports the discovery, development, and commercialization of novel therapeutics by managing investments in research and development and ensuring compliance with financial regulations. By providing strategic financial guidance, Suky Upadhyay enables INCYTE to pursue its mission of addressing unmet medical needs and delivering innovative treatments. The Executive Vice President & Chief Financial Officer's leadership ensures fiscal discipline and optimizes resource deployment across the organization.

Pablo Cagnoni, the President, Global Head of Research & Development at INCYTE, leads the company's scientific exploration and pipeline advancement. Overseeing all research and development activities worldwide, Cagnoni drives the discovery and progression of novel therapeutics from early-stage research through late-stage clinical trials. This leadership function is central to INCYTE's mission of developing innovative treatments for significant unmet medical needs, particularly in oncology. By fostering a collaborative and scientifically rigorous environment, Pablo Cagnoni ensures the efficient and effective translation of scientific breakthroughs into potential patient therapies. The President, Global Head of Research & Development's strategic vision guides the company's investment in cutting-edge science and the expansion of its therapeutic portfolio.

Soni Basi, the Executive Vice President & Chief Human Resources Officer at INCYTE, architects the human capital strategy essential for driving scientific innovation and commercial success. Overseeing all aspects of talent acquisition, development, and retention, Basi ensures INCYTE cultivates a high-performing workforce dedicated to biopharmaceutical advancements. This critical role involves fostering an inclusive and dynamic organizational culture that supports the company's mission to discover and commercialize novel therapeutics. By championing employee engagement and strategic workforce planning, Soni Basi directly contributes to the company's ability to bring life-changing treatments to patients. The Executive Vice President & Chief Human Resources Officer's leadership ensures that INCYTE possesses the talent and organizational infrastructure necessary to navigate the complexities of the pharmaceutical industry.

Andrew Blyton, the Vice President & Chief Information Officer at INCYTE, spearheads the company's technology infrastructure and digital transformation initiatives. Overseeing the development and implementation of robust IT systems, Blyton ensures seamless data management and secure access to critical information supporting drug discovery and development. This leadership position is vital for enabling INCYTE's biopharmaceutical operations, facilitating efficient research, and enhancing overall business processes. By driving technological innovation, Andrew Blyton supports the company's mission to commercialize novel therapeutics and address unmet medical needs. The Vice President & Chief Information Officer's strategic direction ensures that INCYTE leverages cutting-edge technology to maintain a competitive edge in the pharmaceutical landscape.

Steven Stein, the Executive VP, Chief Medical Officer & Head of Late-stage Development at INCYTE, directs the clinical strategy and execution for the company's therapeutic pipeline. Overseeing all late-stage clinical development programs, Stein ensures the rigorous evaluation of novel therapeutics designed to address critical unmet medical needs. This leadership role is paramount in translating scientific discoveries into viable treatments, guiding compounds through regulatory approval processes. By championing patient safety and data integrity, Steven Stein drives INCYTE's commitment to delivering effective and innovative medicines. The Executive VP, Chief Medical Officer & Head of Late-stage Development's expertise ensures that INCYTE's late-stage pipeline progresses efficiently towards potential commercialization, impacting patient care globally.